Incense-fumigating oil of rhizoma atractylodis and folium artemisiae argyi

Abstract

The invention discloses incense-fumigating oil of rhizoma atractylodis and folium artemisiae argyi and relates to a natural plant medicament for external use. The incense-fumigating oil disclosed by the invention is composed of the following botanical medicinal materials in percentage by weight: 80-120 g of rhizoma atractylodis, 80-120 g of folium artemisiae argyi, 40-80 g of agastache rugosus, 40-80 g of herba eupatorii, 40-80 g of clove, 40-80 g of pepper, 40-80 g of amomum cardamomum, 40-80 g of herba elsholtziae, 40-80 g of rhizoma acori graminei, and 20-80 g of rhizoma kaempferiae. The incense-fumigating oil disclosed by the invention is an aromatic oily substance, and taken by way of being inhaled through a nasal cavity, so that the local medicament concentration of a nidus is much higher than that of the whole body, therefore, the incense-fumigating oil can directly act on the nidus part and then quickly kill pathogenic microorganisms; then, the incense-fumigating oil also can enter the blood to regulate the immune system, thereby improving the local sIgA (Immune Gloulin) content of the respiratory tract, protecting the integrity of local respiratory mucosa, and promoting the synthesis and secretion of sIgA. The incense-fumigating oil disclosed by the invention can be used as a preparation which is convenient to use, safe and effective, and has an effect of strengthening the local mucosal immune function, and enhances the mucosa which is the first defense line of the body.

Description

technical field [0001] The invention relates to a natural herbal medicine, and is characterized in that it relates to a medicine for external use. Background technique [0002] Acute upper respiratory tract infection (acute upper respiratory tract infection, AURI), referred to as "upper flu", refers to the general term for acute inflammation of the nasal cavity, pharynx or larynx, and can be divided into common cold, pharyngitis, laryngitis, pharyngoconjunctival fever, bacterial Sexual pharyngo-tonsillitis etc. Modern medicine believes that the infection factors that lead to AURI are mainly viruses, accounting for more than 85% of primary infections [1] , but in developing countries, up to 50% of children with AURI are caused by bacteria [2] . When the virus causes AURI, it is very easy to be combined with bacterial infection. In the 1990s, nearly 1.5 million children in developing countries were deaf each year due to upper respiratory tract infections [3] Therefore,...

AI Technical Summary

Problems solved by technology

Interferon can also improve the local respiratory immune function, but it has certain side effects and is expensive, so it is not easy to popularize and use

At present, preparations for regulating the immune function of local respiratory mucosa and preventing and treating upper respiratory tract infection through nasal inhalation are still rare.